drugset / Trial / NCT05699993

A Study of IBI351 in Healthy Subjects

NCT05699993

Phase 1 Completed 24 enrolled Innovent Biologics (Suzhou) Co. Ltd.
Non-randomizedParallel-groupOpen-labelOther

Summary

This is an open-label, two-cycle clinical study to evaluate the drug interaction between itraconazole or dextromethorphan and IBI351 in healthy subjects. A total of two cohorts of 12 healthy male subjects were planned to be enrolled in each cohort.

Timeline

Start
2023-03-10
Primary completion
2023-10-16
Completion
2023-10-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Dextromethorphan Unknown Oral
Subject IBI351 Small molecule Oral
Subject Itraconazole Small molecule Oral

Indications

No indication recorded.